FDA Determines Regulatory Review Period for Flowmax Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Flowmax, a human drug product, as required by law, following a submission to the Commissioner of Patents and Trademarks, Department of Commerce, for patent extension.